Device and method for drug sensitivity testing of human intestinal cancer organoids

Abstract

The present invention belongs to the technical field of drug sensitivity testing of human intestinal cancer organoids, specifically a device and method for drug sensitivity testing of human intestinal cancer organoids, including a driving component, which is placed on a desktop, and can drive a delivery and identification device to rotate through the driving component. The delivery and identification device is installed on the top of the driving component, and the delivery and identification device is arranged on the upper end of the organoid culture and drug sensitivity testing device. The delivery and identification device can deliver organoids and drugs to the inside of the organoid culture and drug sensitivity testing device, and can observe the cultured and identified organoids in real time. The present invention can perform simultaneous drug sensitivity testing on drug sensitivity reactions of different concentrations of different drugs, thereby eliminating unnecessary repeated operations during operation, while improving the efficiency of drug sensitivity testing and reducing the labor and error rate of testers.

Description

Technical Field

[0001] The present invention relates to the technical field of drug sensitivity testing of human intestinal cancer organoids, and specifically to a device and method for performing drug sensitivity testing on human intestinal cancer organoids. Background Art

[0002] Human colorectal cancer organoids refer to three-dimensional structures that simulate the growth of human colorectal cancer tissue in vitro. This model can be used to study the pathogenesis, drug screening, and treatment strategies of colorectal cancer. Colorectal cancer is one of the most common cancers worldwide, and its incidence has continued to increase in the past few decades. Colorectal cancer is divided into three categories: submucosal cancer, invasive cancer, and metastatic cancer. Submucosal cancer is the earliest type of colorectal cancer, and its cells are located in the submucosal layer; invasive cancer is cancer cells that infiltrate the muscle layer of the intestinal wall but have not spread further; metastatic cancer is the most serious case, and the cancer cells have spread to other organs such as the liver and lungs.

[0003] The drug sensitivity test of human colorectal cancer organoids is an experimental method used to evaluate the sensitivity of different drugs to human colorectal cancer organoids, so as to screen out drugs with strong specificity for patients. This testing method can help doctors develop more accurate and effective treatment plans, reduce the physical pain of multiple chemotherapy for patients, and increase the therapeutic effect of single chemotherapy.

[0004] The existing drug sensitivity test of human colorectal cancer organoids requires a large number of drugs for in vitro testing. The concentrations and properties of different drugs force the drug sensitivity test to prepare a large number of test instruments and repeat a large number of experimental steps, which increases the time of the original drug sensitivity test and increases the burden on testers. To this end, we propose a device and method for drug sensitivity testing of human colorectal cancer organoids. Summary of the invention

[0005] In view of the above-mentioned and / or existing problems in the existing device and method for drug sensitivity testing of human colorectal cancer organoids, the present invention is proposed.

[0006] Therefore, the purpose of the present invention is to provide a device and method for drug sensitivity testing of human colorectal cancer organoids. By driving the driving component and the delivery and identification device, human colorectal cancer organoid tissue and drugs of different concentrations can be delivered into the organoid culture and drug sensitivity testing device, and cell culture, identification and drug sensitivity testing can be performed in the organoid culture and drug sensitivity testing device, which can solve the above-mentioned existing problems.

[0007] To solve the above technical problems, according to one aspect of the present invention, the present invention provides the following technical solutions:

[0008] A device for performing drug sensitivity testing on human intestinal cancer organoids, comprising:

[0009] A driving component is placed on the desktop and can drive the delivery and identification device to rotate through the driving component;

[0010] A delivery and identification device is installed on the top of the driving assembly, and the delivery and identification device is arranged on the upper end of the organoid culture and drug sensitivity testing device, and the delivery and identification device can deliver organoids and drugs into the organoid culture and drug sensitivity testing device, and can observe the cultured and identified organoids in real time;

[0011] A flow rate control device is installed around the surface of the driving component, and the flow rate of the drug and organoid tissue in the organoid culture and drug sensitivity testing device can be controlled by the flow rate control device;

[0012] The organoid culture and drug sensitivity testing device is installed on the top of the flow rate control device, and can receive the organoids and drugs delivered by the delivery and identification device, and culture, identify and perform drug sensitivity testing on the organoid tissue.

[0013] As a preferred solution of the drug sensitivity testing equipment for human colorectal cancer organoids described in the present invention, the driving component includes: a table top, which is placed on the ground; a telescopic rod, which is rotatably connected to the surface center of the table top, and can drive the delivery and identification device to be raised and lowered through the telescopic drive of the telescopic rod; an L-shaped rod, which is arranged at one end of the top of the telescopic rod, and the other end of the L-shaped rod is connected to one end of the outer wall of the delivery and identification device; a rotary drive motor is installed at the bottom center of the table top, and the output end of the rotary drive motor is connected to the bottom of the telescopic rod, and the rotary drive motor can drive the telescopic rod to rotate, thereby driving the delivery and identification device to rotate.

[0014] As a preferred embodiment of the drug sensitivity test device for human intestinal cancer organoids described in the present invention, the delivery and identification device includes: a placement component, the right end of whose outer wall is connected to the end of the L-shaped rod of the driving component; an observation limit component, which is connected to the front end of the placement component, and is connected to a microscope through the observation limit component, so that the organoid tissue in the lower end organoid culture and drug sensitivity test device can be observed; a human intestinal cancer organoid delivery component, which is installed in the middle of the surface of the placement component, and the organoid can be delivered into the organoid culture and drug sensitivity test device through the human intestinal cancer organoid delivery component; a drug delivery component, which is installed at the rear end of the placement component, and the drug can be stored through the drug delivery component, and the drug can be delivered into the organoid culture and drug sensitivity test device.

[0015] As a preferred solution of the drug sensitivity test device for human intestinal cancer organoids described in the present invention, the placement component includes: a placement table, the right end of the outer wall of which is connected to the end of the L-shaped rod of the driving component, and the human intestinal cancer organoid delivery component can be placed through the surface of the placement table; a delivery limit plate, which is arranged at the rear end of the placement table, and the drug delivery component can be placed through the delivery limit plate; an observation plate, which is arranged at the front end of the placement table; a groove, which is arranged at the front and rear ends of the top of the observation plate; a sliding rod, which is arranged inside the groove; an observation groove, which is arranged on the surface of the observation plate, and the observation groove and the front end component of the organoid culture and drug sensitivity test device are on the same vertical plane;

[0016] The observation limit assembly includes: a slider, which is slidably connected to the inside of the groove, and the inside of the slider is slidably connected to the outer wall of the slide rod; an axis plate, which is arranged on the top of the slider; a clamping arc plate, which is rotatably connected to the outer wall of the axis plate; a pressing block, which is arranged at both ends of the bottom of the clamping arc plate; a truncated table, which is slidably connected to the surface of the observation plate, and the clamping arc plate presses the surface of the truncated table, and the sliding of the slider can drive the truncated table to slide; a pressing groove, which is arranged at both ends of the outer wall of the truncated table, and the pressing block is inserted into the inside of the pressing groove, and the clamping arc plate can be connected to the truncated table through the connection of the pressing block; an observation lens, which is arranged at the center of the surface of the truncated table, and the organoid component in the lower end organoid culture and drug sensitivity test device can be magnified through the observation lens, and the upper end of the observation lens is connected to a microscope to observe the organoid component in the organoid culture and drug sensitivity test device in detail;

[0017] The drug delivery component includes: a drug syringe, which is placed on the surface of a delivery limit plate and can store drugs of different concentrations through the drug syringe; an injection tube, which is arranged at the bottom of the drug syringe and is driven by a telescopic rod of a driving component so that the injection tube can be inserted into the interior of a rear end component of an organoid culture and drug sensitivity testing device, thereby enabling the drug to be delivered; an injection air pump, which is arranged at the top of the drug syringe and has an output end connected to the interior of the drug syringe, and the injection air pump can be used to inject gas into the interior of the drug syringe, so that the drug in the drug syringe is injected into the interior of the rear end component of the organoid culture and drug sensitivity testing device through the injection tube.

[0018] As a preferred embodiment of the drug sensitivity test device for human colorectal cancer organoids described in the present invention, the flow rate control device includes: a frame component, which is arranged around the surface of the table of the driving component, and the side-turning component can be placed through the frame component; a limiting component, which is arranged around the outer wall of the frame component, and the side-turning component placed on the surface of the frame component can be limited by the limiting component; the side-turning component is placed on the surface of the frame component, and the organoid culture and drug sensitivity test device is installed on the top of the side-turning component, and the organoid culture and drug sensitivity test device can be placed through the side-turning component; a side-turning driving component, the top of which is connected to the bottom center of the side-turning component, and the bottom is connected to the middle position of the frame component, and through the drive of the side-turning driving component and in cooperation with the limiting component, the side-turning component can be driven to flip in all directions, and at the same time, through the side-turning height of the side-turning driving component, the flow rate of the organoid tissue and drug in the organoid culture and drug sensitivity test device can be regulated.

[0019] As a preferred solution of the drug sensitivity test device for human intestinal cancer organoids described in the present invention, the frame assembly includes: a placement frame, which is arranged around the surface of the table of the driving assembly; a T-shaped bracket, which is arranged inside the placement frame; a first shaft seat, which is arranged on the surface of the T-shaped bracket and connects the first shaft seat to the bottom of the rollover driving assembly; a placement seat, which is arranged around the surface of the placement frame, and the rollover assembly can be placed through the placement seat;

[0020] The limit assembly comprises: an L-shaped mounting plate, which is arranged around the outer wall of the placement frame; a first through groove, which is arranged at the upper end of the inner wall of the L-shaped mounting plate and penetrates the L-shaped mounting plate; a cylinder, which is arranged on the surface of the L-shaped mounting plate; an L-shaped limit rod, one end of the outer wall of which is connected to the output end of the cylinder, and the other end is slidably connected to the inside of the first through groove, and the L-shaped limit rod can be extended to press and limit the rollover assembly;

[0021] The side-turning assembly comprises: a side-turning plate, which is arranged at the upper end of the placing frame; a placing rod, which is arranged around the bottom of the side-turning plate, and the placing rod is placed on the surface of the placing seat, and at the same time, the bottom of the L-shaped limiting rod is in contact with the upper end of the outer wall of the placing rod, and the side-turning plate can be turned over by the cooperation of the placing rod and the placing rod;

[0022] The side rollover drive assembly includes: a second axle seat, which is arranged at the bottom center of the side rollover plate; a first universal shaft, which is rotatably connected between the second axle seat and the top of the first rotating rod, and the second axle seat can be rotatably connected to the first rotating rod through the first universal shaft; the second rotating rod, whose top is rotatably connected to the bottom of the first rotating rod; a U-shaped plate, which is arranged at the bottom of the second rotating rod; a second universal shaft, which is rotatably connected to the inside of the U-shaped plate, and the second universal shaft is connected between the U-shaped plate and the first axle seat, and the U-shaped plate can be rotatably connected to the first axle seat through the second universal shaft; a side rollover drive motor, which is installed at one end of the outer wall of the U-shaped plate, and the output end of the side rollover drive motor is connected to a side port of the second universal shaft, and the first rotating rod and the second rotating rod can be driven to perform a lifting operation through the drive of the side rollover drive motor.

[0023] As a preferred embodiment of the drug sensitivity test device for human colorectal cancer organoids described in the present invention, the organoid culture and drug sensitivity test device includes: a holding component, which is installed on the surface of the flip component of the flow rate control device, and the identification component, the culture component and the drug sensitivity detection component can be driven to rotate by the driving of the holding component; a circulation component, which is arranged on the surface of the holding component, and the organoid tissue and the drug can be circulated through the circulation component; a sealing component, which is arranged on the surface of the circulation component, and the channel in the circulation component can be sealed by the sealing component; an identification component, which is placed on the inner front end of the circulation component, and the bottom of the identification component is It is in contact with the interior of the containing component, and through the cooperation of the containing component and the circulation component, the organoid tissue in the identification component can be circulated and transferred, and through the cooperation of the identification component and the delivery and identification device, the organoid tissue can be identified; the culture component, which is placed in the middle of the interior of the circulation component, and through the cooperation of the culture component and the delivery and identification device, the organoid tissue can be cultured, and through the cooperation of the culture component and the circulation component, the organoid tissue can be transferred to the interior of the identification component for identification; the drug sensitivity detection component, which is placed at the rear end of the interior of the circulation component, and through the drug sensitivity detection component, the organoid tissue can be tested for drug sensitivity to drugs of different concentrations.

[0024] As a preferred embodiment of the drug sensitivity test device for human intestinal cancer organoids described in the present invention, the holding component includes: a holding base, which is installed on the surface of the flip component of the flow rate control device; a first holding tank, which is arranged at the front end of the surface of the holding base, and the lower end of the first holding tank is provided with a built-in motor, and the identification component can be rotationally driven by the built-in motor; an adjustment drive motor is arranged at the middle end of the inner part of the holding base; a second holding tank, which is arranged at the center of the holding base, and the holding plate inside the second holding tank is connected to the driving end of the adjustment drive motor, and the holding plate inside the second holding tank can be rotated by the adjustment drive motor, so as to drive the culture component to rotate; a third holding tank, which is arranged at the rear end of the surface of the holding base, and the lower end of the third holding tank is provided with a built-in motor, and the drug sensitivity detection component can be rotationally driven by the built-in motor;

[0025] The circulation component includes: a circulation bottom plate, which is arranged on the surface of the holding base; a bottom plate groove, which is arranged around the surface of the circulation bottom plate, and the bottom plate groove is connected with the first holding groove, the second holding groove and the third holding groove; a circulation plate, which is arranged on the surface of the circulation bottom plate; a first circulation groove, which is arranged at the internal front end of the circulation plate; a second circulation groove, which is arranged in the middle of the circulation plate; a third circulation groove, which is arranged at the internal rear end of the circulation plate; a circulation pipeline, which is connected between the first circulation groove and the second circulation groove, and between the second circulation groove and the third circulation groove, and organoid tissue and drugs can be circulated through the circulation pipeline; a discharge pipeline, one end of which is connected to one end of the second circulation groove, and the other end is connected to one end of the outer wall of the circulation plate, and the material in the second circulation groove can be discharged through the discharge pipeline.

[0026] As a preferred solution of the drug sensitivity test device for human intestinal cancer organoids described in the present invention, the sealing assembly includes: a sealing plate, which is installed on the surface of the circulation plate and can seal the circulation pipeline and the discharge pipeline through the sealing plate; a second through groove, which is arranged on the surface of the sealing plate and connects the second through groove with the first circulation groove, the second circulation groove and the third circulation groove;

[0027] The identification component includes: an identification vessel, which penetrates the second through groove, the first flow groove and the bottom plate groove, and allows the bottom of the identification vessel to be contained in the first containing groove; a first electric valve, which is arranged at one end of the outer wall of the identification vessel, and through the opening of the first electric valve, the organoid tissue in the identification vessel can be discharged; an identification cover plate, which is arranged on the top of the identification vessel; an observation plate, which is arranged on the surface of the identification cover plate, and the organoid tissue inside the identification vessel can be observed through the observation plate; a pressing telescopic rod, the top of which is arranged at the two ends of the bottom of the identification cover plate, and the bottom is connected to the two ends of the top of the pressing plate; the pressing plate, by pressing the telescopic rod, the pressing plate can press the organoid tissue inside the identification vessel, so that the observation lens of the delivery and identification device can magnify the structure of the internal organoid tissue, and at the same time, the organoid tissue can be identified by cooperating with a microscope;

[0028] The culture component includes: a culture vessel, which penetrates the second through groove, the second flow groove and the bottom plate groove, and the bottom of the culture vessel is placed inside the second holding groove; a second electric valve, which is arranged at one end of the outer wall of the culture vessel, and the culture solution in the second electric valve can be discharged by opening the second electric valve; a motor, which is installed at the top center of the culture vessel; a baffle, which is arranged around the bottom of the cover of the culture vessel; a filter, which is installed in the gap between the baffles, and the culture solution and the organoid tissue can be separated by the filter; a rotating shaft, the top of which is connected to the output end of the motor, and the rotating shaft can be driven to rotate by the motor; a movable baffle, which is installed around the upper end and the lower end of the outer wall of the rotating shaft, and the movable baffles are arranged in a plurality of groups, and the plurality of groups of movable baffles at the upper end and the plurality of groups of movable baffles at the lower end are arranged in an alternating manner;

[0029] The drug sensitivity detection component includes: a drug sensitivity vessel, which runs through the second through groove, the third flow groove and the bottom plate groove, and the bottom of the drug sensitivity vessel is placed inside the third holding groove, and an injection port is provided on the top of the drug sensitivity vessel, and the drug can be injected into the interior of the drug sensitivity vessel through the injection port for drug sensitivity reaction; a third electrical valve, which is arranged at one end of the outer wall of the drug sensitivity vessel, and by opening the third electrical valve, the cultured and identified organoid tissue can be transferred to the interior of the drug sensitivity vessel for drug sensitivity detection.

[0030] A method for drug sensitivity testing of human intestinal cancer organoids, comprising the following steps:

[0031] S1: Place the extracted organoids into the human intestinal cancer organoid delivery component, deliver the organoids into the culture vessel through the human intestinal cancer organoid delivery component, and then add a sufficient amount of culture buffer washing solution into the culture vessel;

[0032] S2: The culture vessel is centrifugally cleaned by adjusting the driving motor, and then the movable baffle at the lower end is opened by starting the motor, so that a fine gap of the filter screen appears between the movable baffle and the baffle, and the culture buffer cleaning liquid after centrifugation is completely discharged, and the second electric valve is adjusted to the discharge pipe by adjusting the driving motor, and the culture buffer cleaning liquid is discharged by the flipping of the discharge pipe and the flow rate control device. At this time, the primary intestinal cancer tissue digestion liquid is injected into the interior of the culture vessel, and the primary intestinal cancer tissue digestion liquid digests the organoid tissue at room temperature until the organoid tissue presents cell clusters, and then the culture buffer cleaning liquid is added again to terminate the digestion;

[0033] S3: At this time, the motor is started to drive the movable baffle to rotate along the inner wall of the baffle in a contact manner, and the regulating drive motor is started to drive the culture vessel to rotate in the opposite direction, so that the cell clusters in the culture vessel are ground between the movable baffle and the baffle, and then filtered to the outer area of ​​the baffle through the filter. At this time, the culture vessel is allowed to settle statically. After a period of time, the human intestinal cancer organoid delivery component is started again, and the needle at the bottom of the human intestinal cancer organoid delivery component is inserted into the injection port at the top of the culture vessel to absorb the supernatant in the outer area, and a sufficient amount of CO is injected into the interior of the culture vessel to culture the human intestinal cancer organoids;

[0034] S4: After the human intestinal cancer organoids are cultured, the human intestinal cancer organoids are discharged into a group of identification vessels by flipping the flow rate control device and cooperating with the second electric valve and the flow pipe, and the culture vessels are replaced, and the above operation is repeated until the human intestinal cancer organoids are filled in several groups of culture vessels;

[0035] S5: At this time, the human intestinal cancer organoid tissue is subjected to HE staining identification, immunofluorescence identification and gene sequencing identification. When different identification solutions are added, the pressing telescopic rod can be started to operate the pressing telescopic rod to press and limit the human intestinal cancer organoid tissue, and then the round table can be moved to move the observation lens to the upper end of the identification vessel. At this time, the identification result can be observed and confirmed through the microscope through the observation lens, the observation plate and the pressing transparent film, and then the qualified human intestinal cancer organoid tissue is turned over into the clean culture vessel through the first electrical valve of the identification vessel and the flow rate control device;

[0036] S6: The qualified human colorectal cancer organoid tissues are then evenly distributed to several groups of drug-sensitive vessels through the cooperation of the second electrical valve of the culture vessel and the flipping of the flow rate control device. At this time, the telescopic rod is activated to drive the injection tube of the drug syringe to be inserted into the interior of several groups of drug-sensitive vessels, and the prepared drugs of different concentrations are injected into the drug-sensitive vessels. The human colorectal cancer organoid tissues in the drug-sensitive vessels are subjected to drug sensitivity tests of different concentrations under the same drug state. By setting up several groups of flow rate control devices and organoid culture and drug sensitivity testing devices, drug sensitivity tests of different concentrations can be performed on multiple drugs, so as to compare the most suitable drugs.

[0037] Compared with existing technologies:

[0038] Through the cooperation of the driving component, the delivery and identification device, and the organoid culture and drug sensitivity testing device, human intestinal cancer organoid tissues and drugs of different concentrations can be delivered to several groups of organoid culture and drug sensitivity testing devices, and human intestinal cancer organoid tissues in the organoid culture and drug sensitivity testing devices can be identified and observed to determine qualified human intestinal cancer organoid cell clusters;

[0039] Through the coordination of the flow rate control device with the organoid culture and drug sensitivity testing device, the flow of liquid in all directions can be guided, which facilitates the flow of tissue liquid, human intestinal cancer organoid cell clusters and excess drugs. At the same time, by adjusting the tilt angle of the flip, the flow rate of tissue liquid, human intestinal cancer organoid cell clusters and excess drugs can be controlled, thereby regulating the culture reaction.

[0040] By performing the three-step operations of culture, identification and drug sensitivity in the organoid culture and drug sensitivity testing device, and setting the organoid culture and drug sensitivity testing device into several groups, it is possible to perform simultaneous drug sensitivity tests on drug sensitivity reactions of different concentrations of different drugs, thereby eliminating unnecessary repeated operations during the operation, while improving the efficiency of drug sensitivity testing, reducing the labor and error rate of testers, and being able to determine the appropriate type and concentration of drugs required for drug sensitivity testing, thereby reducing the variability and uncertainty of the final results. BRIEF DESCRIPTION OF THE DRAWINGS

[0041] Figure 1 A schematic diagram of the overall main structure provided by the present invention;

[0042] Figure 2 A schematic diagram of the structure of the drive assembly provided by the present invention;

[0043] Figure 3 A bottom view schematic diagram of the driving assembly provided by the present invention;

[0044] Figure 4 This is a schematic diagram of the disassembled structure of the delivery and identification device provided by the present invention;

[0045] Figure 5 A schematic diagram of the split structure of the placement component provided by the present invention;

[0046] Figure 6 A schematic diagram of the disassembled structure of the drug delivery component provided by the present invention;

[0047] Figure 7 A schematic diagram of the disassembly structure of the observation limit assembly provided by the present invention;

[0048] Figure 8 A schematic diagram of the split structure of the flow rate control device and the organoid culture and drug sensitivity testing device provided by the present invention;

[0049] Fig. 9 A schematic diagram of the split structure of the flow rate control device provided by the present invention;

[0050] Fig.10 A schematic diagram of the connection structure of the frame assembly provided by the present invention;

[0051] Fig.11 A schematic diagram of the structure of the limit assembly provided by the present invention;

[0052] Fig.12 A schematic diagram of the rollover assembly structure provided by the present invention;

[0053] Fig.13 A schematic diagram of the rollover drive assembly structure provided by the present invention;

[0054] Fig.14 A schematic diagram of the structure of the organoid culture and drug sensitivity testing device provided by the present invention;

[0055] Fig.15 This is a schematic diagram of the disassembled structure of the organoid culture and drug sensitivity testing device provided by the present invention;

[0056] Fig.16 A schematic diagram of the structure of a containing assembly provided by the present invention;

[0057] Fig.17 A schematic diagram of the structure of the circulation assembly provided by the present invention;

[0058] Fig.18 A schematic diagram of the structure of the drug sensitivity detection component provided by the present invention;

[0059] Fig.19 A schematic diagram of the split structure of the culture component provided by the present invention;

[0060] Fig. 20 A schematic diagram of the internal structure of the culture component provided by the present invention;

[0061] Fig.21 This is a schematic diagram of the disassembly structure of the identification component provided by the present invention.

[0062] In the figure: driving component 1, table 11, telescopic rod 12, L-shaped rod 13, rotating driving motor 14, delivery and identification device 2, placement component 21, placement table 211, delivery limit plate 212, observation plate 213, groove 214, slide bar 215, observation groove 216, observation limit component 22, slider 221, shaft plate 222, clamping arc plate 223, pressing block 224, round table 225, pressing groove 226, observation lens 227, human intestinal cancer organoid delivery component 23, drug delivery Component 24, drug syringe 241, injection tube 242, injection air pump 243, flow rate control device 3, frame component 31, placement frame 311, T-shaped bracket 312, first shaft seat 313, placement seat 314, limit component 32, L-shaped mounting plate 321, first through groove 322, cylinder 323, L-shaped limit rod 324, rollover component 33, rollover plate 331, placement rod 332, rollover drive component 34, second shaft seat 341, first universal shaft 342, first rotating rod 343 , second rotating rod 344, U-shaped plate 345, second universal shaft 346, rollover drive motor 347, organoid culture and drug sensitivity testing device 4, holding component 41, holding base 411, first holding slot 412, adjustment drive motor 413, second holding slot 414, third holding slot 415, circulation component 42, circulation bottom plate 421, bottom plate slot 422, circulation plate 423, first circulation slot 424, circulation pipeline 425, second circulation slot 426, discharge pipeline 427, third circulation Groove 428, sealing assembly 43, sealing plate 431, second through groove 432, identification assembly 44, identification vessel 441, first electrical valve 442, identification cover 443, observation transparent plate 444, pressing telescopic rod 445, pressing transparent sheet 446, culture assembly 45, culture vessel 451, second electrical valve 452, motor 453, baffle 454, filter 455, rotating shaft 456, movable baffle 457, drug sensitivity detection assembly 46, drug sensitivity vessel 461, third electrical valve 462. DETAILED DESCRIPTION

[0063] To make the objectives, technical solutions and advantages of the present invention more clear, the embodiments of the present invention will be further described in detail below with reference to the accompanying drawings.

[0064] The present invention provides a device and method for drug sensitivity testing of human intestinal cancer organoids. Figure 1-21 , including a driving component 1, a delivery and identification device 2, a flow rate control device 3, and an organoid culture and drug sensitivity testing device 4;

[0065] A driving component 1 is placed on a desktop, and can drive the delivery and identification device 2 to be driven for rotation through the driving component 1. The driving component 1 includes: a table 11, a telescopic rod 12, an L-shaped rod 13 and a rotation driving motor 14. The table 11 is placed on the ground. The telescopic rod 12 is rotatably connected to the center of the surface of the table 11, and can drive the delivery and identification device 2 to be raised and lowered through the telescopic drive of the telescopic rod 12. The L-shaped rod 13 is arranged at one end of the top of the telescopic rod 12, and the other end of the L-shaped rod 13 is connected to one end of the outer wall of the delivery and identification device 2. The rotation driving motor 14 is installed at the bottom center of the table 11, and the output end of the rotation driving motor 14 is connected to the bottom of the telescopic rod 12. The rotation driving motor 14 can drive the telescopic rod 12 to rotate, thereby driving the delivery and identification device 2 to rotate.

[0066] The delivery and identification device 2 is installed on the top of the driving component 1, and the delivery and identification device 2 is set at the upper end of the organoid culture and drug sensitivity testing device 4, and the delivery and identification device 2 can be used to deliver organoids and drugs into the organoid culture and drug sensitivity testing device 4, and can observe the cultured and identified organoids in real time. The delivery and identification device 2 includes: a placement component 21, a placement table 211, a delivery limit plate 212, an observation plate 213, a groove 214, a slide bar 215, an observation groove 216, an observation limit component 22, a slider 221, an axis plate 222, a clamping arc plate 223, a pressing block 224, a round table 225, a pressing groove 226, an observation lens 227, a human intestinal cancer organoid delivery component 23, and a drug delivery component 24. A drug syringe 241, an injection tube 242 and an injection air pump 243, a placement component 21, the right end of whose outer wall is connected to the end of the L-shaped rod 13 of the driving component 1, a placement table 211, the right end of whose outer wall is connected to the end of the L-shaped rod 13 of the driving component 1, and the human colorectal cancer organoid delivery component 23 can be placed through the surface of the placement table 211, a delivery limit plate 212, which is arranged at the rear end of the placement table 211, and the drug delivery component 24 can be placed through the delivery limit plate 212, an observation plate 213, which is arranged at the front end of the placement table 211, a groove 214, which is arranged at the front and rear ends of the top of the observation plate 213, a sliding rod 215, which is arranged inside the groove 214, and an observation groove 216, which is arranged at the observation The surface of the plate 213 is arranged so that the observation groove 216 and the front end component of the organoid culture and drug sensitivity testing device 4 are in the same vertical plane, the observation limit component 22 is connected to the front end of the placement component 21, and the microscope is connected through the observation limit component 22, so that the organoid tissue in the lower end organoid culture and drug sensitivity testing device 4 can be observed, the slider 221 is slidably connected to the inside of the groove 214, and the inside of the slider 221 is slidably connected to the outer wall of the slide bar 215, the shaft plate 222 is arranged on the top of the slider 221, the clamping arc plate 223 is rotatably connected to the outer wall of the shaft plate 222, the pressing block 224 is arranged at the two ends of the bottom of the clamping arc plate 223, the round table 225 is slidably connected to the surface of the observation plate 213, and The clamping arc plate 223 is made to press the surface of the truncated table 225, and the sliding of the slider 221 can drive the truncated table 225 to slide. The pressing groove 226 is arranged at both ends of the outer wall of the truncated table 225, and the pressing block 224 is inserted into the pressing groove 226. The clamping arc plate 223 and the truncated table 225 can be connected through the connection of the pressing block 224. The observation lens 227 is arranged at the center of the surface of the truncated table 225, and the organoid component in the lower end organoid culture and drug sensitivity test device 4 can be magnified through the observation lens 227, and a microscope is connected to the upper end of the observation lens 227 to observe the organoid component in the organoid culture and drug sensitivity test device 4 in detail. Human intestinal cancer organoid delivery component 23,It is installed in the middle of the surface of the placement component 21, and can release the organoid into the organoid culture and drug sensitivity testing device 4 through the human intestinal cancer organoid release component 23. The drug release component 24 is installed at the rear end of the placement component 21, and can store the drug through the drug release component 24, and can release the drug into the organoid culture and drug sensitivity testing device 4. The drug syringe 241 is placed on the surface of the release limit plate 212, and can store drugs of different concentrations through the drug syringe 241. The injection tube 242 is arranged on the drug release plate 212. The bottom of the drug syringe 241 is connected to the bottom of the drug syringe 241, and driven by the telescopic rod 12 of the driving component 1, the injection tube 242 can be inserted into the rear end component of the organoid culture and drug sensitivity testing device 4, so that the drug can be injected. The injection air pump 243 is arranged on the top of the drug syringe 241, and the output end is connected to the inside of the drug syringe 241. The injection air pump 243 can inject gas into the inside of the drug syringe 241, so that the drug in the drug syringe 241 is injected into the rear end component of the organoid culture and drug sensitivity testing device 4 through the injection tube 242.

[0067] The flow rate control device 3 is installed around the surface of the driving component 1, and the flow rate control device 3 can control the flow rate of the drugs and organoid tissues in the organoid culture and drug sensitivity testing device 4. The flow rate control device 3 includes: a frame component 31, a placement frame 311, a T-shaped bracket 312, a first shaft seat 313, a placement seat 314, a limit component 32, an L-shaped mounting plate 321, a first through groove 322, a cylinder 323, an L-shaped limit rod 324, a rollover component 33, a rollover plate 331, a placement rod 332, a rollover drive component 34, a second shaft seat 341, a first universal shaft 342, a first rotating rod 343, a second rotating rod 344, a U-shaped plate 345, a second universal shaft 346 and a rollover drive motor 347. The frame component 31, which is arranged around the surface of the table 11 of the driving component 1, and the rollover component 33 can be placed through the frame component 31, the placement frame 311, which is arranged around the surface of the table 11 of the driving component 1, the T-shaped bracket 312, which is arranged inside the placement frame 311, the first shaft seat 313, which is arranged on the surface of the T-shaped bracket 312, and the first shaft seat 313 is connected to the bottom of the rollover driving component 34, the placement seat 314, which is arranged around the surface of the placement frame 311, and the rollover component 33 can be placed through the placement seat 314, and the limiting component 32 is arranged around the outer wall of the frame component 31, and the rollover component 33 placed on the surface of the frame component 31 can be limited by the limiting component 32. The L-shaped mounting plate 321 is arranged around the outer wall of the placing frame 311, the first through groove 322 is arranged on the upper end of the inner wall of the L-shaped mounting plate 321 and passes through the L-shaped mounting plate 321, the cylinder 323 is arranged on the surface of the L-shaped mounting plate 321, and the L-shaped limiting rod 324, one end of the outer wall of which is connected to the output end of the cylinder 323, and the other end is slidably connected to the inside of the first through groove 322, and the L-shaped limiting rod 324 is extended to enable the L-shaped limiting rod 324 to press and limit the rollover assembly 33, the rollover assembly 33 is placed on the surface of the frame assembly 31, and the organoid culture and drug sensitivity testing device 4 is installed on the top of the rollover assembly 33, and the organoid culture and drug sensitivity testing device can be controlled by the rollover assembly 33. 4 is placed, the side flip plate 331 is arranged at the upper end of the placement frame 311, the placement rod 332 is arranged around the bottom of the side flip plate 331, and the placement rod 332 is placed on the surface of the placement seat 314, and at the same time, the bottom of the L-shaped limiting rod 324 is in contact with the upper end of the outer wall of the placement rod 332, and the side flip plate 331 can be flipped by the cooperation of the placement rod 332 and the placement rod 332, and the side flip drive component 34, the top of which is connected to the bottom center of the side flip component 33, and the bottom is connected to the middle position of the frame component 31, and through the drive of the side flip drive component 34 and the cooperation with the limiting component 32, the side flip component 33 can be driven to flip in all directions, and at the same time, through the side flip height of the side flip drive component 34,The flow rate of the organoid tissue and the drug in the organoid culture and drug sensitivity testing device 4 can be regulated, the second shaft seat 341 is arranged at the bottom center of the side flap 331, the first universal shaft 342 is rotatably connected between the second shaft seat 341 and the top of the first rotating rod 343, and the second shaft seat 341 can be rotatably connected to the first rotating rod 343 through the first universal shaft 342, the second rotating rod 344, the top of which is rotatably connected to the bottom of the first rotating rod 343, the U-shaped plate 345 is arranged at the bottom of the second rotating rod 344, and the second universal shaft 342 is rotatably connected to the first rotating rod 343. The second universal shaft 346 is rotatably connected to the inside of the U-shaped plate 345, and the second universal shaft 346 is connected between the U-shaped plate 345 and the first shaft seat 313, and the U-shaped plate 345 and the first shaft seat 313 can be rotatably connected through the second universal shaft 346. The rollover drive motor 347 is installed at one end of the outer wall of the U-shaped plate 345, and the output end of the rollover drive motor 347 is connected to a side port of the second universal shaft 346. The first rotating rod 343 and the second rotating rod 344 can be driven to perform a jacking operation through the drive of the rollover drive motor 347.

[0068] The organoid culture and drug sensitivity testing device 4 is installed on the top of the flow rate control device 3, and can receive the organoids and drugs released by the release and identification device 2 through the organoid culture and drug sensitivity testing device 4, and culture, identify and perform drug sensitivity testing on the organoid tissue. The organoid culture and drug sensitivity testing device 4 includes: a holding component 41, a holding base 411, a first holding slot 412, an adjustment drive motor 413, a second holding slot 414, a third holding slot 415, a circulation component 42, a circulation bottom plate 421, a bottom plate slot 422, a circulation plate 423, a first circulation slot 424, a circulation pipe 425, a second circulation slot 426, a discharge pipe 427, a third circulation slot 428, a sealing component 43, a sealing plate 431, a second The through groove 432, the identification component 44, the identification vessel 441, the first electrical valve 442, the identification cover 443, the observation transparent plate 444, the pressing telescopic rod 445, the pressing transparent sheet 446, the culture component 45, the culture vessel 451, the second electrical valve 452, the motor 453, the baffle 454, the filter 455, the rotating shaft 456, the movable baffle 457, the drug sensitivity detection component 46, the drug sensitivity vessel 461 and the third electrical valve 462, the holding component 41, which is installed on the surface of the side flip component 33 of the flow rate control device 3, and the identification component 44, the culture component 45 and the drug sensitivity detection component 46 can be driven to rotate by the driving of the holding component 41, the holding base 411, which is installed on the surface of the side flip component 33 of the flow rate control device 3, the first A holding tank 412 is provided at the front end of the surface of the holding base 411, and a built-in motor is provided at the lower end of the first holding tank 412, and the identification component 44 can be rotationally driven by the built-in motor. An adjusting drive motor 413 is provided at the middle end of the holding base 411. A second holding tank 414 is provided at the center of the holding base 411, and the holding plate inside the second holding tank 414 is connected to the driving end of the adjusting drive motor 413, and the holding plate inside the second holding tank 414 can be rotated by the adjusting drive motor 413, so as to drive the culture component 45 to be rotationally driven. A third holding tank 415 is provided at the rear end of the surface of the holding base 411, and the inside of the third holding tank 415 A built-in motor is provided at the lower end, and the drug sensitivity detection component 46 contained therein can be rotationally driven by the built-in motor. A circulation component 42 is arranged on the surface of the containing component 41, and the organoid tissue and the drug can be circulated through the circulation component 42. A circulation bottom plate 421 is arranged on the surface of the containing base 411. A bottom plate groove 422 is arranged around the surface of the circulation bottom plate 421, and the bottom plate groove 422 is connected with the first containing groove 412, the second containing groove 414 and the third containing groove 415. A circulation plate 423 is arranged on the surface of the circulation bottom plate 421. A first circulation groove 424 is arranged at the inner front end of the circulation plate 423. A second circulation groove 426 is arranged in the inner middle of the circulation plate 423. A third circulation groove 428,It is arranged at the inner rear end of the circulation plate 423, the circulation pipe 425, which is connected between the first circulation groove 424 and the second circulation groove 426, and between the second circulation groove 426 and the third circulation groove 428, and the organoid tissue and the drug can be circulated through the circulation pipe 425, the discharge pipe 427, one end of which is connected to one end of the second circulation groove 426, and the other end is connected to one end of the outer wall of the circulation plate 423, and the substance in the second circulation groove 426 can be discharged through the discharge pipe 427, the sealing component 43, which is arranged on the surface of the circulation component 42, and the channel in the circulation component 42 can be sealed by the sealing component 43, and the sealing plate 431, which is installed on the surface of the circulation plate 423, and the sealing plate 431 is installed on the surface of the circulation plate 423. 1 can seal the circulation channel 425 and the discharge channel 427, the second through groove 432 is arranged on the surface of the sealing plate 431, and the second through groove 432 is connected with the first circulation groove 424, the second circulation groove 426 and the third circulation groove 428, the identification component 44 is placed at the front end of the circulation component 42, and the bottom of the identification component 44 is in contact with the inside of the containing component 41, and through the cooperation of the containing component 41 and the circulation component 42, the organoid tissue in the identification component 44 can be circulated and transferred, and at the same time, the identification component 44 cooperates with the delivery and identification device 2 to identify the organoid tissue, and the identification vessel 441 runs through the second through groove 432, the first circulation groove 424 and the bottom plate groove 422, The bottom of the identification vessel 441 is placed inside the first containing groove 412. The first electric valve 442 is arranged at one end of the outer wall of the identification vessel 441. By opening the first electric valve 442, the organoid tissue in the identification vessel 441 can be discharged. The identification cover 443 is arranged on the top of the identification vessel 441. The observation plate 444 is arranged on the surface of the identification cover 443. The organoid tissue inside the identification vessel 441 can be observed through the observation plate 444. The top of the pressing telescopic rod 445 is arranged at the two ends of the bottom of the identification cover 443. The bottom is connected to the two ends of the top of the pressing transparent sheet 446. The pressing transparent sheet 446 can press the pressing telescopic rod 445 to press the pressing transparent sheet 446 to the identification vessel 441. The organoid tissue inside the vessel 441 is pressed, so that the observation lens 227 of the delivery and identification device 2 can magnify the structure of the internal organoid tissue. At the same time, the organoid tissue can be identified by cooperating with a microscope. The culture component 45 is placed in the middle of the circulation component 42, and the organoid tissue can be cultured by cooperating with the delivery and identification device 2, and the organoid tissue can be transferred to the identification component 44 for identification by cooperating with the culture component 45 and the circulation component 42. The culture vessel 451 passes through the second through groove 432, the second circulation groove 426 and the bottom plate groove 422, and the bottom of the culture vessel 451 is placed inside the second holding groove 414. The second electric valve 452,It is arranged at one end of the outer wall of the culture vessel 451, and by opening the second electric valve 452, the culture fluid in the second electric valve 452 can be discharged, the motor 453 is installed at the top center of the culture vessel 451, the baffle 454 is arranged around the bottom of the cover of the culture vessel 451, the filter 455 is installed in the gap between the baffles 454, and the culture fluid and the organoid tissue can be separated by the filter 455, the rotating shaft 456, the top of which is connected to the output end of the motor 453, and the rotating shaft 456 can be driven to rotate by the drive of the motor 453, and the movable baffle 457 is installed around the upper end and the lower end of the outer wall of the rotating shaft 456, and the movable baffle 457 is arranged in a plurality of groups, and the upper end of the plurality of groups of movable baffles 45 7 and several groups of movable baffles 457 at the lower end are arranged in an interlaced manner, a drug sensitivity detection component 46 is placed at the rear end of the circulation component 42, and the drug sensitivity detection component 46 can be used to test the drug sensitivity of organoid tissue to drugs of different concentrations, a drug sensitivity vessel 461, which penetrates the second through groove 432, the third circulation groove 428 and the bottom plate groove 422, and the bottom of the drug sensitivity vessel 461 is placed inside the third holding groove 415, and the top of the drug sensitivity vessel 461 is provided with an injection port, and the drug can be injected into the drug sensitivity vessel 461 through the injection port for drug sensitivity reaction, and a third electrical valve 462 is arranged at one end of the outer wall of the drug sensitivity vessel 461, and by opening the third electrical valve 462, the cultured and identified organoid tissue can be transferred to the inside of the drug sensitivity vessel 461 for drug sensitivity detection.

[0069] During specific use, a technician in this field will place the extracted organoid into the human intestinal cancer organoid delivery component 23, and deliver the organoid into the culture vessel 451 through the human intestinal cancer organoid delivery component 23, and then deliver a sufficient amount of culture buffer cleaning solution into the culture vessel 451, and centrifuge the culture vessel 451 by adjusting the drive motor 413, and then start the motor 453 to open the movable baffle 457 at the lower end, so that a fine gap of the filter screen 455 appears between the movable baffle 457 and the baffle 454, and the culture buffer cleaning solution after centrifugation is completely discharged, and adjust the second electrical valve 452 to the discharge pipe 427 by adjusting the drive motor 413, and the culture vessel 451 is turned over and matched with the discharge pipe 427 and the flow rate control device 3. The buffer cleaning liquid is discharged, and the primary intestinal cancer tissue digestion liquid is injected into the interior of the culture vessel 451, so that the primary intestinal cancer tissue digestion liquid digests the organoid tissue at room temperature until the organoid tissue presents cell clusters, and then the culture buffer cleaning liquid is added again to terminate the digestion. At this time, the motor 453 is started to drive the movable baffle 457 to rotate along the inner wall of the baffle 454 in a contact manner, and the adjustment drive motor 413 is started to drive the culture vessel 451 to rotate in the opposite direction, so that the cell clusters in the culture vessel 451 are ground between the movable baffle 457 and the baffle 454, and then filtered to the outer area of ​​the baffle 454 through the filter screen 455. At this time, the culture vessel 451 is allowed to settle statically. After a period of time, the human intestinal cancer organoid delivery component 23 is started again to allow the human The needle at the bottom of the intestinal cancer organoid delivery component 23 is inserted into the injection port at the top of the culture vessel 451 to absorb the supernatant in the external area, and a sufficient amount of CO2 is injected into the culture vessel 451 to culture the human intestinal cancer organoid. After the culture of the human intestinal cancer organoid is completed, the flow rate control device 3 is flipped, and the second electrical valve 452 and the flow pipe 425 are used to discharge the human intestinal cancer organoid tissue into a group of identification vessels 441, and the culture vessel 451 is replaced. The above operation is repeated until the interior of several groups of culture vessels 451 are filled with human intestinal cancer organoid tissue. At this time, the human intestinal cancer organoid tissue is subjected to HE staining identification, immunofluorescence identification and gene sequencing identification. When adding different identification solutions, the expansion and contraction can be started by pressing Rod 445 is used to press the telescopic rod 445 to operate the pressing transparent plate 446 to press and limit the human intestinal cancer organoid tissue, and then the observation lens 227 is moved to the upper end of the identification vessel 441 by moving the round table 225. At this time, the identification result can be observed and confirmed through a microscope through the observation lens 227, the observation transparent plate 444 and the pressing transparent plate 446, and then the qualified human intestinal cancer organoid tissue is passed through the first electrical valve 442 of the identification vessel 441 and the flipping of the flow rate control device 3 into the clean culture vessel 451, and then the qualified human intestinal cancer organoid tissue is evenly distributed to several groups of drug-sensitive vessels 461 through the cooperation of the second electrical valve 452 of the culture vessel 451 and the flipping of the flow rate control device 3. At this time, by starting the telescopic rod 12,The injection tube 242 driving the drug syringe 241 is inserted into the interior of several groups of drug sensitivity vessels 461, and the prepared drugs of different concentrations are injected into the drug sensitivity vessels 461, and the drug sensitivity test of different concentrations of human intestinal cancer organoid tissues in the drug sensitivity vessels 461 under the same drug state is performed. By setting several groups of flow rate control devices 3 and organoid culture and drug sensitivity testing devices 4, drug sensitivity tests of different concentrations of multiple drugs can be performed, so as to compare the most suitable drugs.

[0070] Although the present invention has been described above with reference to the embodiments, various modifications may be made thereto and parts thereof may be replaced by equivalents without departing from the scope of the present invention. In particular, as long as there is no structural conflict, the various features in the embodiments disclosed in the present invention may be used in combination with each other in any manner, and the fact that these combinations are not exhaustively described in this specification is only for the sake of omitting space and saving resources. Therefore, the present invention is not limited to the specific embodiments disclosed herein, but includes all technical solutions falling within the scope of the claims.

Claims

1. A device for drug sensitivity testing of human intestinal cancer organoids, comprising: A driving component (1) is placed on a desktop, and can drive the delivery and identification device (2) to rotate through the driving component (1); The device is characterized in that: the delivery and identification device (2) is installed on the top of the driving component (1), and the delivery and identification device (2) is arranged on the upper end of the organoid culture and drug sensitivity testing device (4), and the delivery and identification device (2) can deliver organoids and drugs into the organoid culture and drug sensitivity testing device (4), and can observe the cultured and identified organoids in real time; A flow rate control device (3) is installed around the surface of the driving component (1), and the flow rate of the drug and organoid tissue in the organoid culture and drug sensitivity testing device (4) can be controlled by the flow rate control device (3); An organoid culture and drug sensitivity testing device (4) is installed on the top of the flow rate control device (3), and can receive the organoids and drugs delivered by the delivery and identification device (2) through the organoid culture and drug sensitivity testing device (4), and perform operations of culture, identification and drug sensitivity testing on the organoid tissue; The flow rate control device (3) comprises: A frame assembly (31) is arranged around the surface of the tabletop (11) of the driving assembly (1), and the rollover assembly (33) can be placed through the frame assembly (31); A limiting assembly (32) is arranged around the outer wall of the frame assembly (31), and the limiting assembly (32) can limit the rollover assembly (33) placed on the surface of the frame assembly (31); A side-turning assembly (33) is placed on the surface of the frame assembly (31), and the organoid culture and drug sensitivity testing device (4) is installed on the top of the side-turning assembly (33), and the organoid culture and drug sensitivity testing device (4) can be placed through the side-turning assembly (33); A rollover drive assembly (34), the top of which is connected to the bottom center of the rollover assembly (33), and the bottom of which is connected to the middle position of the frame assembly (31). The rollover drive assembly (34) is driven and cooperates with the limit assembly (32) to drive the rollover assembly (33) to roll over in all directions. At the same time, the flow rate of the organoid tissue and the drug in the organoid culture and drug sensitivity testing device (4) can be regulated by the rollover height of the rollover drive assembly (34); The organoid culture and drug sensitivity testing device (4) comprises: A containing component (41) is mounted on the surface of the side-turning component (33) of the flow rate control device (3), and the identification component (44), the culture component (45) and the drug sensitivity detection component (46) can be driven to rotate by driving the containing component (41); A circulation component (42), which is disposed on the surface of the containing component (41), and through which the organoid tissue and the drug can be circulated; A sealing component (43) is arranged on the surface of the circulation component (42), and the channel in the circulation component (42) can be sealed by the sealing component (43); An identification component (44) is placed at the front end of the circulation component (42), and the bottom of the identification component (44) is in contact with the inside of the containing component (41). The containing component (41) cooperates with the circulation component (42) to transfer the organoid tissue in the identification component (44). At the same time, the identification component (44) cooperates with the delivery and identification device (2) to identify the organoid tissue. A culture component (45) is placed in the middle of the circulation component (42), and the culture component (45) cooperates with the delivery and identification device (2) to culture the organoid tissue, and the culture component (45) cooperates with the circulation component (42) to transfer the organoid tissue to the identification component (44) for identification; The drug sensitivity detection component (46) is placed at the rear end of the circulation component (42), and the drug sensitivity detection component (46) can be used to perform drug sensitivity tests on organoid tissues to drugs of different concentrations. The containing component (41) comprises: A containing base (411) mounted on the surface of the side-turning assembly (33) of the flow rate control device (3); A first containing groove (412) is arranged at the front end of the surface of the containing base (411), and a built-in motor is provided at the lower end of the first containing groove (412), and the contained identification component (44) can be rotationally driven by the built-in motor; An adjusting driving motor (413) is arranged at a middle end inside the containing base (411); A second containing tank (414) is arranged at the center of the containing base (411), and a containing plate inside the second containing tank (414) is connected to a driving end of an adjusting driving motor (413), and the containing plate inside the second containing tank (414) can be rotated by adjusting the driving motor (413), thereby driving the culture component (45) to be rotationally driven; A third containing groove (415) is arranged at the rear end of the surface of the containing base (411), and a built-in motor is provided at the lower end of the interior of the third containing groove (415), and the contained drug sensitivity detection component (46) can be rotationally driven by the built-in motor; The circulation component (42) comprises: A circulation bottom plate (421) disposed on a surface of the containing base (411); A bottom plate groove (422) is arranged around the surface of the circulation bottom plate (421), and the bottom plate groove (422) is connected to the first containing groove (412), the second containing groove (414) and the third containing groove (415); A circulation plate (423) disposed on the surface of the circulation bottom plate (421); A first circulation groove (424) disposed at the inner front end of the circulation plate (423); A second circulation slot (426) disposed in the middle of the circulation plate (423); A third circulation slot (428) disposed at the inner rear end of the circulation plate (423); A circulation conduit (425), which is connected between the first circulation groove (424) and the second circulation groove (426), and between the second circulation groove (426) and the third circulation groove (428), and the organoid tissue and the drug can be circulated through the circulation conduit (425); A discharge pipe (427) has one end connected to one end of the second flow groove (426) and the other end connected to one end of the outer wall of the flow plate (423), and the material in the second flow groove (426) can be discharged through the discharge pipe (427). The sealing assembly (43) comprises: A sealing plate (431) is installed on the surface of the circulation plate (423), and the circulation pipe (425) and the discharge pipe (427) can be sealed by the sealing plate (431); A second through groove (432) is provided on the surface of the sealing plate (431) and enables the second through groove (432) to communicate with the first circulation groove (424), the second circulation groove (426) and the third circulation groove (428); The identification component (44) comprises: An identification vessel (441) passes through the second through groove (432), the first flow groove (424) and the bottom plate groove (422), and the bottom of the identification vessel (441) is placed inside the first containing groove (412); A first electric valve (442) is disposed at one end of the outer wall of the identification vessel (441), and the organoid tissue in the identification vessel (441) can be discharged by opening the first electric valve (442); An identification cover plate (443) disposed on the top of the identification vessel (441); An observation plate (444) is disposed on the surface of the identification cover plate (443), and the organoid tissue inside the identification vessel (441) can be observed through the observation plate (444); A pressing telescopic rod (445), the top of which is arranged at the two ends of the bottom of the identification cover plate (443), and the bottom is connected to the two ends of the top of the pressing transparent sheet (446); A pressing transparent sheet (446) can press the pressing transparent sheet (446) on the organoid tissue inside the identification vessel (441) by pressing the telescopic rod (445), so that the observation lens (227) of the delivery and identification device (2) can magnify the structure of the internal organoid tissue, and at the same time, the organoid tissue can be identified by cooperating with a microscope; The culture assembly (45) comprises: A culture vessel (451) that penetrates the second through groove (432), the second circulation groove (426), and the bottom plate groove (422), and allows the bottom of the culture vessel (451) to be placed inside the second holding groove (414); A second electric valve (452) is arranged at one end of the outer wall of the culture vessel (451), and the culture liquid in the second electric valve (452) can be discharged by opening the second electric valve (452); A motor (453) mounted at the top center of the culture vessel (451); A baffle (454) is arranged around the bottom of the cover of the culture vessel (451); A filter (455) is installed in the gap between the baffles (454), and the culture medium and the organoid tissue can be separated through the filter (455); A rotating shaft (456) whose top is connected to the output end of the motor (453) and can be driven by the motor (453) to drive the rotating shaft (456) to rotate; The movable baffles (457) are installed around the upper end and the lower end of the outer wall of the rotating shaft (456), and the movable baffles (457) are arranged in a plurality of groups, and the upper plurality of groups of movable baffles (457) and the lower plurality of groups of movable baffles (457) are arranged in an alternating manner; The drug sensitivity detection component (46) comprises: The drug-sensitive vessel (461) penetrates the second through groove (432), the third flow groove (428) and the bottom plate groove (422), and the bottom of the drug-sensitive vessel (461) is placed inside the third holding groove (415), and the top of the drug-sensitive vessel (461) is provided with an injection port, and the drug can be injected into the drug-sensitive vessel (461) through the injection port to perform a drug-sensitive reaction; The third electrical valve (462) is arranged at one end of the outer wall of the drug-sensitive vessel (461), and by opening the third electrical valve (462), the cultured and identified organoid tissue can be transferred to the interior of the drug-sensitive vessel (461) for drug sensitivity testing.

2. The device for drug sensitivity testing of human intestinal cancer organoids according to claim 1, characterized in that: The driving assembly (1) comprises: A table top (11) placed on the ground; A telescopic rod (12) is rotatably connected to the center of the surface of the table (11), and the delivery and identification device (2) can be driven to move up and down by the telescopic drive of the telescopic rod (12); An L-shaped rod (13) is arranged at one end of the top of the telescopic rod (12), and the other end of the L-shaped rod (13) is connected to one end of the outer wall of the delivery and identification device (2); A rotary drive motor (14) is mounted at the bottom center of the table (11), and the output end of the rotary drive motor (14) is connected to the bottom of the telescopic rod (12). The rotary drive motor (14) can drive the telescopic rod (12) to rotate, thereby driving the delivery and identification device (2) to rotate.

3. The device for drug sensitivity testing of human intestinal cancer organoids according to claim 2, characterized in that: The delivery and identification device (2) comprises: A placement assembly (21) having a right end of an outer wall connected to the end of an L-shaped rod (13) of the drive assembly (1); An observation stopper component (22) connected to the front end of the placement component (21) and connected to a microscope via the observation stopper component (22) so as to be able to observe the organoid tissue in the lower end organoid culture and drug sensitivity testing device (4); A human intestinal cancer organoid delivery component (23), which is installed in the middle of the surface of the placement component (21), and through the human intestinal cancer organoid delivery component (23), the organoid can be delivered into the organoid culture and drug sensitivity testing device (4); The drug delivery component (24) is installed at the rear end of the placement component (21), and the drug delivery component (24) can be used to store drugs and deliver the drugs into the organoid culture and drug sensitivity testing device (4).

4. The device for drug sensitivity testing of human intestinal cancer organoids according to claim 3, characterized in that: The placement component (21) comprises: A placement table (211), the right end of the outer wall of which is connected to the end of the L-shaped rod (13) of the driving component (1), and the human intestinal cancer organoid delivery component (23) can be placed on the surface of the placement table (211); A delivery limiting plate (212) is arranged at the rear end of the placement table (211), and the medicine delivery component (24) can be placed through the delivery limiting plate (212); An observation panel (213) disposed at the front end of the placement table (211); Grooves (214) are provided at the front and rear ends of the top of the observation plate (213); A slide bar (215) disposed inside the groove (214); An observation tank (216) is arranged on the surface of the observation plate (213), and the observation tank (216) and the front end component of the organoid culture and drug sensitivity testing device (4) are located on the same vertical plane; The observation limit assembly (22) comprises: A slider (221) is slidably connected to the inside of the groove (214), and the inside of the slider (221) is slidably connected to the outer wall of the slide rod (215); A shaft plate (222) disposed on the top of the slider (221); A clamping arc plate (223) rotatably connected to the outer wall of the shaft plate (222); Pressing blocks (224) are arranged at two ends of the bottom of the clamping arc plate (223); The round table (225) is slidably connected to the surface of the observation plate (213), and the clamping arc plate (223) presses the surface of the round table (225), and the sliding of the slider (221) can drive the round table (225) to slide; Pressing grooves (226) are arranged at both ends of the outer wall of the truncated table (225), and the pressing blocks (224) are inserted into the pressing grooves (226). Through the connection of the pressing blocks (224), the clamping arc plate (223) and the truncated table (225) can be connected; An observation lens (227) is arranged at the center of the surface of the truncated table (225), and the organoid components in the lower end organoid culture and drug sensitivity testing device (4) can be magnified through the observation lens (227), and a microscope is connected to the upper end of the observation lens (227) to observe the organoid components in the organoid culture and drug sensitivity testing device (4) in detail; The drug delivery component (24) comprises: A drug syringe (241) is placed on the surface of the delivery limit plate (212), and drugs of different concentrations can be stored through the drug syringe (241); An injection tube (242) is arranged at the bottom of the drug syringe (241) and is driven by the telescopic rod (12) of the driving component (1) so that the injection tube (242) can be inserted into the interior of the rear end component of the organoid culture and drug sensitivity testing device (4), thereby enabling the drug to be injected; An injection air pump (243) is arranged on the top of the drug syringe (241) and has an output end connected to the interior of the drug syringe (241). The injection air pump (243) can inject air into the interior of the drug syringe (241), so that the drug in the drug syringe (241) is injected into the interior of the rear end component of the organoid culture and drug sensitivity testing device (4) through the injection tube (242).

5. The device for drug sensitivity testing of human intestinal cancer organoids according to claim 4, characterized in that: The frame assembly (31) comprises: A placement frame (311) is arranged around the surface of the table (11) of the driving assembly (1); A T-shaped bracket (312) disposed inside the placement frame (311); A first axle seat (313) is arranged on the surface of the T-shaped bracket (312), and the first axle seat (313) is connected to the bottom of the rollover drive assembly (34); A placement seat (314) is arranged around the surface of the placement frame (311), and the rollover assembly (33) can be placed through the placement seat (314); The limiting component (32) comprises: An L-shaped mounting plate (321) is arranged around the outer wall of the placement frame (311); A first through groove (322), which is arranged at the upper end of the inner wall of the L-shaped mounting plate (321) and passes through the L-shaped mounting plate (321); A cylinder (323) disposed on a surface of the L-shaped mounting plate (321); An L-shaped limiting rod (324), one end of the outer wall of which is connected to the output end of the cylinder (323), and the other end of which is slidably connected to the inside of the first through groove (322), and by extending the L-shaped limiting rod (324), the L-shaped limiting rod (324) can press and limit the rollover assembly (33); The rollover assembly (33) comprises: A side flap (331) disposed at the upper end of the placement frame (311); A placement rod (332) is arranged around the bottom of the side flip plate (331), and the placement rod (332) is placed on the surface of the placement seat (314). At the same time, the bottom of the L-shaped limiting rod (324) is in contact with the upper end of the outer wall of the placement rod (332). Through the cooperation between the placement rod (332) and the placement rod (332), the side flip plate (331) can be flipped sideways. The rollover drive assembly (34) comprises: A second axle seat (341) is arranged at the bottom center of the side flap (331); A first universal shaft (342) is rotatably connected between the second shaft seat (341) and the top of the first rotating rod (343), and the second shaft seat (341) and the first rotating rod (343) can be rotatably connected via the first universal shaft (342); A second rotating rod (344), the top of which is rotatably connected to the bottom of the first rotating rod (343); A U-shaped plate (345) disposed at the bottom of the second rotating rod (344); A second universal shaft (346) is rotatably connected to the inside of the U-shaped plate (345), and the second universal shaft (346) is connected between the U-shaped plate (345) and the first shaft seat (313), and the U-shaped plate (345) and the first shaft seat (313) can be rotatably connected via the second universal shaft (346); The rollover drive motor (347) is mounted on one end of the outer wall of the U-shaped plate (345), and the output end of the rollover drive motor (347) is connected to a side port of the second universal shaft (346). The rollover drive motor (347) is driven to drive the first rotating rod (343) and the second rotating rod (344) to perform a lifting operation.

6. A method for drug sensitivity testing of human intestinal cancer organoids according to claims 1-5, characterized in that: The steps include: S1: placing the extracted organoid into the human intestinal cancer organoid delivery component (23), delivering the organoid into the culture vessel (451) through the human intestinal cancer organoid delivery component (23), and then delivering a sufficient amount of culture buffer washing solution into the culture vessel (451); S2: The culture vessel (451) is centrifuged and cleaned by adjusting the driving motor (413), and then the motor (453) is started to open the movable baffle (457) at the lower end, so that a fine gap of the filter (455) appears between the movable baffle (457) and the baffle (454), and the culture buffer cleaning liquid after centrifugation is completely discharged, and the second electric valve (452) is adjusted to the discharge pipe (427) by adjusting the driving motor (413), and the culture buffer cleaning liquid is discharged by the cooperation of the discharge pipe (427) and the flow rate control device (3) to turn over, and then the primary intestinal cancer tissue digestion liquid is injected into the interior of the culture vessel (451), so that the primary intestinal cancer tissue digestion liquid digests the organoid tissue at room temperature, until the organoid tissue presents cell clusters, and then the culture buffer cleaning liquid is added again to terminate the digestion; S3: At this time, the motor (453) is started to drive the movable baffle (457) to rotate along the inner wall of the baffle (454) in a contact manner, and the regulating drive motor (413) is started to drive the culture vessel (451) to rotate in the opposite direction, so that the cell mass in the culture vessel (451) is ground between the movable baffle (457) and the baffle (454), and then filtered through the filter (455) to the outer area of ​​the baffle (454). At this time, the culture vessel (451) is allowed to settle statically. After a period of time, the human intestinal cancer organoid delivery component (23) is started again, and the needle at the bottom of the human intestinal cancer organoid delivery component (23) is inserted into the injection port at the top of the culture vessel (451), the supernatant in the outer area is sucked, and a sufficient amount of CO2 is injected into the interior of the culture vessel (451) to culture the human intestinal cancer organoid; S4: After the human intestinal cancer organoids are cultured, the flow rate control device (3) is flipped and the second electrical valve (452) and the flow pipe (425) are coordinated to discharge the human intestinal cancer organoids into a group of identification vessels (441), and the culture vessels (451) are replaced. The above operation is repeated until the human intestinal cancer organoids are filled in several groups of culture vessels (451); S5: At this time, the human intestinal cancer organoid tissue is subjected to HE staining identification, immunofluorescence identification and gene sequencing identification. When different identification solutions are added, the pressing telescopic rod (445) can be started to operate the pressing telescopic rod (445) to press and limit the human intestinal cancer organoid tissue, and then the observation lens (227) can be moved to the upper end of the identification vessel (441) by moving the round table (225). At this time, the identification result can be observed and confirmed through a microscope through the observation lens (227), the observation plate (444) and the pressing translucent film (446), and then the qualified human intestinal cancer organoid tissue is passed through the first electrical valve (442) of the identification vessel (441) and the flow rate control device (3) is turned over to enter the clean culture vessel (451); S6: The qualified human intestinal cancer organoid tissues are then evenly distributed to a plurality of groups of drug-sensitive vessels (461) by the cooperation of the second electric valve (452) of the culture vessel (451) and the flipping of the flow rate control device (3). At this time, the telescopic rod (12) is activated to drive the injection tube (242) of the drug syringe (241) to be inserted into the plurality of groups of drug-sensitive vessels (461), and the prepared drugs of different concentrations are injected into the drug-sensitive vessels (461). The human intestinal cancer organoid tissues in the drug-sensitive vessels (461) are subjected to drug sensitivity tests of different concentrations under the same drug state. By setting up a plurality of groups of flow rate control devices (3) and organoid culture and drug sensitivity testing devices (4), drug sensitivity tests of different concentrations can be performed on a plurality of drugs, thereby matching the most suitable drug.

Images